BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 19276158)

  • 1. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
    Xie H; Valera VA; Merino MJ; Amato AM; Signoretti S; Linehan WM; Sukhatme VP; Seth P
    Mol Cancer Ther; 2009 Mar; 8(3):626-35. PubMed ID: 19276158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
    Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
    Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
    Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
    Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.
    Linehan WM; Rouault TA
    Clin Cancer Res; 2013 Jul; 19(13):3345-52. PubMed ID: 23633457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.
    Ashrafian H; O'Flaherty L; Adam J; Steeples V; Chung YL; East P; Vanharanta S; Lehtonen H; Nye E; Hatipoglu E; Miranda M; Howarth K; Shukla D; Troy H; Griffiths J; Spencer-Dene B; Yusuf M; Volpi E; Maxwell PH; Stamp G; Poulsom R; Pugh CW; Costa B; Bardella C; Di Renzo MF; Kotlikoff MI; Launonen V; Aaltonen L; El-Bahrawy M; Tomlinson I; Pollard PJ
    Cancer Res; 2010 Nov; 70(22):9153-65. PubMed ID: 20978192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF and fumarate hydratase in renal cancer.
    Sudarshan S; Linehan WM; Neckers L
    Br J Cancer; 2007 Feb; 96(3):403-7. PubMed ID: 17211469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
    Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
    Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.
    Sudarshan S; Sourbier C; Kong HS; Block K; Valera Romero VA; Yang Y; Galindo C; Mollapour M; Scroggins B; Goode N; Lee MJ; Gourlay CW; Trepel J; Linehan WM; Neckers L
    Mol Cell Biol; 2009 Aug; 29(15):4080-90. PubMed ID: 19470762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
    Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
    PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary leiomyomatosis and renal cell cancer (HLRCC).
    Kiuru M; Launonen V
    Curr Mol Med; 2004 Dec; 4(8):869-75. PubMed ID: 15579034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.
    Alam NA; Rowan AJ; Wortham NC; Pollard PJ; Mitchell M; Tyrer JP; Barclay E; Calonje E; Manek S; Adams SJ; Bowers PW; Burrows NP; Charles-Holmes R; Cook LJ; Daly BM; Ford GP; Fuller LC; Hadfield-Jones SE; Hardwick N; Highet AS; Keefe M; MacDonald-Hull SP; Potts ED; Crone M; Wilkinson S; Camacho-Martinez F; Jablonska S; Ratnavel R; MacDonald A; Mann RJ; Grice K; Guillet G; Lewis-Jones MS; McGrath H; Seukeran DC; Morrison PJ; Fleming S; Rahman S; Kelsell D; Leigh I; Olpin S; Tomlinson IP
    Hum Mol Genet; 2003 Jun; 12(11):1241-52. PubMed ID: 12761039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
    Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
    Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
    Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
    Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
    Bayley JP; Launonen V; Tomlinson IP
    BMC Med Genet; 2008 Mar; 9():20. PubMed ID: 18366737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spatholobus suberectus on breast cancer.
    Wang Z; Wang D; Han S; Wang N; Mo F; Loo TY; Shen J; Huang H; Chen J
    PLoS One; 2013; 8(2):e56631. PubMed ID: 23457597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
    Toro JR; Nickerson ML; Wei MH; Warren MB; Glenn GM; Turner ML; Stewart L; Duray P; Tourre O; Sharma N; Choyke P; Stratton P; Merino M; Walther MM; Linehan WM; Schmidt LS; Zbar B
    Am J Hum Genet; 2003 Jul; 73(1):95-106. PubMed ID: 12772087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review: Warburg effect and renal cancer caused by errs in fumarate hydratase encoding gene.
    Qureshi AS; Ali S
    Pak J Pharm Sci; 2019 Mar; 32(2):743-749. PubMed ID: 31081789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fumarate hydratase deficiency and cancer: activation of hypoxia signaling?
    Ratcliffe PJ
    Cancer Cell; 2007 Apr; 11(4):303-5. PubMed ID: 17418405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.